Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Patients and data tracking

- PMLiVE

Havas Life London appoints Fran Griffin as Head of Strategy

Griffin moves from BBH London to Havas Health

- PMLiVE

The Rashomon Effect

Why your cross-functional team gets cross

- PMLiVE

Stories of sickness: applying illness narratives to health advertising

By Dr Stephanie Goley Introduction As advertisers, we know that health and pharmaceutical campaigns hold enormous influence over how the public perceives illness, wellness, and treatment. But too often, our...

11 London

Young girl receives vaccine jab in her arm

Regaining trust in childhood vaccines: can better comms turn the tables on hesitancy and misinformation?

In the wake of Trump questioning MMR vaccines, we review the best practices in vaccine communications and consider how to reverse damage done to public trust in childhood vaccinations.

Say Communications

- PMLiVE

Medscape Education: Pioneering Pathways at ESMO 2025

Medscape Oncology will be pioneering pathways at the 2025 ESMO congress taking place in Berlin, Germany this October.

Medscape Education

- PMLiVE

PMLiVE’s T40 – now open for submissions!

Healthcare agencies can submit their entries free of charge with a deadline of 30 October

- PMLiVE

Roche’s small cell lung cancer therapy approved by FDA

This is the first and only approved combination therapy for extensive-stage small cell lung cancer

- PMLiVE

Indegene acquires BioPharm to advance AI-driven life sciences marketing

The acquisition strengthens Indegene’s AI-enabled commercialisation and AdTech capabilities

- PMLiVE

The impact of US tariffs on healthcare and life sciences multinationals

Ensuring business continuity across clinical, operational and commercial stages

- PMLiVE

Eli Lilly’s Inluriyo approved by FDA for breast cancer

The oral drug can be used to treat advanced or metastatic breast cancer

- PMLiVE

FDA accepts supplemental New Drug Application for Pharming’s paediatric immunodeficiency therapy

If approved, the treatment would be the first for children with APDS under 12 years

- PMLiVE

Porterhouse appoints Jennifer Stewart as Medical Director in US

Jennifer brings over a decade of experience working in biopharma

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links